Sensus Healthcare Q2 Results: Company to report earnings on August 13
Sensus Healthcare Inc will announce Q2 2026 earnings on August 13, 2026, followed by a management conference call. The medical device firm, known for non-invasive skin cancer treatments, will discuss financial performance and business updates. Investors can join via phone or live webcast.
*this image is generated using AI for illustrative purposes only.
Sensus Healthcare, Inc. (NASDAQ: SRTS) will report its financial results for the second quarter of 2026 on Thursday, August 13, 2026. The medical device company, which specializes in non-invasive treatments for oncological and non-oncological skin conditions, will also hold a business update conference call beginning at 4:30 pm Eastern time. Investors are advised to monitor the release for key metrics regarding revenue, net profit, and operational progress in its superficial radiotherapy segment.
The conference call is designed to review the quarterly results, provide a broader business update, and answer questions from analysts and investors. Participants are encouraged to pre-register using the provided link to receive a unique dial-in number, which allows them to bypass the live operator. Pre-registration can be completed at any time, including up to and after the call start time.
For those unable to pre-register, access to the conference call is available by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Callers should ask the operator to connect them to the Sensus Healthcare conference call. This ensures seamless access for all stakeholders interested in the company’s latest financial performance.
| Access Method | Details |
|---|---|
| Date | August 13, 2026 |
| Time | 4:30 pm Eastern |
| U.S./Canada Dial-in | 844-481-2811 |
| International Dial-in | 412-317-0676 |
| Webcast | Available via Investor Relations |
The call will also be webcast live and can be accessed through the company’s website or the dedicated event link. The live stream will be archived in the Investor Relations section of www.sensushealthcare.com for later viewing. This provides flexibility for global investors who may not be able to attend the live session due to time zone differences.
Sensus Healthcare operates as a global pioneer in developing non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company offers healthcare providers a patient-centric treatment platform. The firm emphasizes safety, precision, and adaptability across various clinical settings in radiation oncology.
Investor relations inquiries can be directed to Leigh Salvo at New Street Investor Relations via email at leigh@newstreetir.com . As the results date approaches, market participants will likely focus on any updates regarding product adoption rates, regulatory developments, or strategic partnerships that could influence future growth trajectories.
How might Sensus Healthcare's Q2 2026 revenue performance influence its valuation relative to competitors in the non-invasive oncology treatment space?
What specific regulatory milestones or FDA approvals could be discussed during the conference call that would accelerate the adoption of IG-SRT technology?
Are there indications of new strategic partnerships or market expansion efforts in international regions that could drive future growth beyond the U.S. and Canada?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
